Show metadata Hide metadata

(19)

(11)

2 539 797

(13)

(51)

IPC

C07K14/61(2006-01-01)

A61K38/37(2006-01-01)

(21) (22)

Application

2011133926/10, 2010-01-22

(24)

Start date

2010-01-22

(22)

Actual filing date

2010-01-22

(45)

Published

2015-01-27

(72)

Inventor

Olsen Ole Khvil'StedBrajnkhol'T JensS'Edt Kristine BruunDemjut KhelleNerskov-Lauritsen LeifTjugesen Peter

(73)

Holder

Novo Nordisk Khels Kea Ag

HUMAN GROWTH HORMONE DERIVATIVE HIGHLY RESISTANT TO PROTEOLYTIC DEGRADATION, METHOD FOR PREPARING THIS DERIVATIVE, USING IT, METHOD OF TREATING, AND PHARMACEUTICAL COMPOSITION Russian patent published in 2015 - IPC C07K14/61 A61K38/37

Abstract RU 2539797 C2

FIELD: medicine.

SUBSTANCE: invention refers to molecular biology, medicine, biochemistry and gene engineering. Presented is a human growth hormone derivative containing an additional disulphide bond as compared to hGh defined by SEQ ID No. 1, wherein the derivative contains at least one pair of mutations described by H21C/M170C, D26/V102C, D26/Y103C, F54C/Y143C, F54C/S144C, S55C/Y143C, S57C/Y143C, I58C/Q141C, I58C/Y143C, I58C/S144C, P59C/Q137C, S71C/S132C, L81C/Y143C, Q84C/Y143C, S85C/Y143C, S85C/S144C, F92C/T148C and/or R94C/D107C in SEQ ID No. 1, and possesses the activity of the human growth hormone, as well as a method for preparing this derivative, using it, a method of treating and a pharmaceutical composition.

EFFECT: invention possesses high stability and resistance to proteolytic degradation as a consequence of the introduction of cysteine residues.

18 cl, 3 dwg, 6 tbl, 5 ex

Similar patents RU2539797C2

Title	Year	Author	Number
GROWTH HORMONES WITH PROLONGED EFFICACY IN VIVO	2011	Berens Karsten Jokhansen Nils Langeland Andersen Khenrik Sun Nerskov-Laupittsen, Lajf Bukardt Ens	RU2605627C2
APPLICATION OF GROWTH HORMONE FRAGMENTS	2012	Kenley David	RU2639474C2
NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE	2019	Shin Cheongbyeol Jang Dooseo Moon Ji Hye Kim Dong Hyun Lee Ji Eun	RU2805873C2
HYBRID STRUCTURE, INCLUDING ANTIGEN-BINDING FRAGMENT SPECIFIC TO SERUM ALBUMIN AND EFFECTOR COMPONENT AND METHODS FOR PREPARATION THEREOF	2014	Chkha Sankhun	RU2661087C2
CHIMERIC PROTEIN PROVIDING FORMATION OF BIOACTIVE CONFORMATION, METHOD FOR PREPARING PROTEIN WITH INSULIN ACTIVITY, METHOD FOR IDENTIFICATION OF PEPTIDYL FRAGMENT	1998	Gan Zkhongru	RU2238951C2
FUSED PROTEIN OR PEPTIDE WITH INCREASED HALF LIFETIME IN VIVO, WHICH IS MAINTAINED DUE TO SLOW RELEASE IN VIVO, AND METHOD FOR INCREASING HALF LIFETIME IN VIVO USING IT	2010	Chung Khue-Sin Ju Song Bum Li Sang Mi	RU2503688C2
COVALENTLY LINKED CONJUGATES CHELICAR-ANTIBODY AGAINST CHELICAR AND USE THEREOF	2014	Brinkmann Ulrikh Georges Gaj Khoffmann Ajke Tifentaler Georg Messner Ekkekhard Dengl Stefan Gertner Akhim	RU2694981C2
THERAPEUTIC FUSION PROTEINS	2012	Cheddok Dzhon Kharper Elejn	RU2651492C2
METHOD OF CONJUGATING PEPTIDES, MEDIATED BY TRANSGLUTAMINASE	2005	Jokhansen Nil'S Langeland Sundel' Magali Derval'D Florensio Saragosa	RU2385879C2
SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS	2016	Hill, Oliver Gieffers, Christian Thiemann, Meinolf Schnyder, Tim	RU2745801C2

RU 2 539 797 C2

Authors

Olsen Ole Khvil'Sted

Brajnkhol'T Jens

S'Edt Kristine Bruun

Demjut Khelle

Nerskov-Lauritsen Leif

Tjugesen Peter

Dates

2015-01-27—Published

2010-01-22—Filed